UNSPSC 51142309: Levallorphan tartrate

This classification denotes an opiate antagonist with the molecular formula C19H25NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U0VSF7HTN0, chemically known as 2h-10,4a-iminoethanophenanthren-6-ol, 11-allyl-1,3,4,9,10,10a-hexahydro-, tartrate but more generally known as levallorphan tartrate, which bears US NIH Compound Identifier 5464111. European Medicines Agency schedules Levallorphan tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02901MIG.

UNSPSC 51142309 Levallorphan tartrate is a Commodity code that in recent state and local activity tracks pharmaceutical procurement more broadly than the code name alone suggests. State and local governments are sourcing naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs through this classification. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). Vendors must typically meet federal and state pharmaceutical compliance requirements, including Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, FDA approval, and in some cases federal funding conditions such as Clean Air Act and Federal Water Pollution Control Act adherence. Contracts generally span two years with optional renewals, require E-Verify employment verification and drug-free workplace certification, and mandate specific insurance coverage limits.

Recent activity centers in Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, due July 26, 2023 (note: posted date June 30, 2026 but due date appears to reflect an earlier solicitation cycle). The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's MMCAP published RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026 and awards effective July 1, 2026. The MMCAP solicitation weighted price competitiveness at 75 percent of evaluation and required 3 percent administrative fees on all purchases.